Announcements Trials
Browse Landscape

Phase

Phase 1/2 8Phase 2 7Phase 3 5Phase 4 3Phase 1 3Phase 2/3 1

Status

Completed 3

Sponsor Class

OTHER 12NIH 6NETWORK 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Endocrine 1

Conditions

Neoplasms 1522Carcinoma, Non-Small-Cell Lung 758Breast Neoplasms 572Neoplasm Metastasis 531Colorectal Neoplasms 448Melanoma 390Leukemia, Myeloid, Acute 371Multiple Myeloma 364Ovarian Neoplasms 354Recurrence 336Lymphoma 334Advanced Solid Tumors 326Lymphoma, Non-Hodgkin 315Prostatic Neoplasms 302Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 234Carcinoma, Renal Cell 226Squamous Cell Carcinoma of Head and Neck 211Lung Neoplasms 211Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 185Solid Tumors 183Carcinoma, Hepatocellular 165Hematologic Neoplasms 155Head and Neck Neoplasms 153Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

vandetanib 1Ranitidine 1Omeprazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Carcinoma, Medullary × Clear all
NCT03780517 2023-10-30

Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors

Boston Pharmaceuticals

Phase 1 Completed
117 enrolled
EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a

NCT01539655 2017-05-02

Vandetanib

Sanofi

Phase 1 Completed
34 enrolled

Carcinoma, Medullary

NCT00215605 2013-02-27

Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

Exelixis

Phase 1 Completed
85 enrolled
Head & NeckLymphoid

Lymphoma, Neoplasms, Thyroid Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡